Quantifying Environmental Waste From Diabetes Devices in the U.S.

Copenhagen Declaration: a transformative vision for global diabetes.

Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.

Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec.

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.

No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6.

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.